(Q34788204)

4 August 2017

1 reference

title

Use of bacille Calmette-Guérin in superficial bladder cancer (English)

1 reference

4 August 2017

Meyer JP

1

1 reference

4 August 2017

Persad R

series ordinal

2

1 reference

4 August 2017

Gillatt DA

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Postgraduate Medical Journal

4 August 2017

published in

1 reference

4 August 2017

volume

78

1 reference

4 August 2017

issue

922

1 reference

4 August 2017

page(s)

449-454

1 reference

The management of superficial bladder cancer

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

BCG intravesical instillations: recommendations for side-effects management

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Long-term survival of patients with bladder tumours: the significance of risk factors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

HLA-DR expression by high grade superficial bladder cancer treated with BCG.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Internalization of bacille Calmette-Guerin by bladder tumor cells.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Long-term results of intravesical therapy for superficial bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Outcome in carcinoma in situ of bladder treated with intravesical bacille Calmette-Guérin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Interference of modern antibacterials with bacillus Calmette-Guerin viability.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742458

Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression

26 October 2018

1 reference

12 December 2020

Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder

1 reference

12 December 2020

Active immunotherapy for acute lymphoblastic leukaemia

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Prognostic parameters in superficial bladder cancer: an analysis of 315 cases

1 reference

12 December 2020

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

1 reference

12 December 2020

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

1 reference

12 December 2020

Role of fibronectin in intravesical BCG therapy for superficial bladder cancer

1 reference

12 December 2020

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

1 reference

12 December 2020

Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer

1 reference

12 December 2020

T-cell subsets required for intravesical BCG immunotherapy for bladder cancer

1 reference

12 December 2020

Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group

1 reference

12 December 2020

Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder

1 reference

12 December 2020

A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder

1 reference

12 December 2020

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1136/PMJ.78.922.449

1 reference

4 August 2017

1 reference

4 August 2017

1 reference